Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients

Lung Cancer

Volumn 107, Issue , 2017, Pages 100-107

  Sorber, L ^a,b   Zwaenepoel, K ^a,b   Deschoolmeester, V ^a,b   Van Schil, P E Y ^b   Van Meerbeeck, J ^a,b   Lardon, F ^a   Rolfo, C ^b   Pauwels, P ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cell free DNA; Liquid biopsy; Non small cell lung cancer; Platelets; Tumor related RNA

Indexed keywords

CELL FREE NUCLEIC ACID; CHLOROPLAST DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; NUCLEIC ACID; RNA; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ARTICLE; CANCER PATIENT; DNA DETERMINATION; FOLLOW UP; GENE MUTATION; HUMAN; LIQUID BIOPSY; LUNG CANCER; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTE; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR VOLUME; BLOOD; CANCER STAGING; DRUG RESISTANCE; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROCEDURES; PROGNOSIS;

BIOMARKERS, TUMOR; BLOOD PLATELETS; CARCINOMA, NON-SMALL-CELL LUNG; CELL-FREE NUCLEIC ACIDS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIQUID BIOPSY; LUNG NEOPLASMS; MUTATION; NEOPLASM STAGING; PRECISION MEDICINE; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84970021896     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.04.026     Document Type: Article

References (105)

1. [1] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman D: global cancer statistics. CA Cancer J. Clin. 61 (2011), 69–90.
2. [2] Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511: 543–550.
3. [3] Rosell, R., Karachaliou, N., Large-scale screening for somatic mutations in lung cancer. Lancet 387 (2016), 1354–1356.
4. [4] Chan, B.A., Hughes, B.G., Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl. Lung Cancer Res. 4 (2015), 36–54.
5. [5] Alamgeer, M., Ganju, V., Watkins, D.N., Novel therapeutic targets in non-small cell lung cancer. Curr. Opin. Pharmacol. 13 (2013), 394–401.
6. [6] Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T., Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S., Nukiwa, T., North-East Japan Study G. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362 (2010), 2380–2388.
7. [7] Vanderlaan, P.A., Yamaguchi, N., Folch, E., Boucher, D.H., Kent, M.S., Gangadharan, S.P., Majid, A., Goldstein, M.A., Huberman, M.S., Kocher, O.N., Costa, D.B., Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer 84 (2014), 39–44.
8. [8] Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr., Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
9. [9] Mendel P, Mandel L, et al., [Not Available]. C R Hebd Seances Acad Sci 1948;226: 2019–2021.
10. [10] Lo, Y.M., Chiu, R.W., Genomic analysis of fetal nucleic acids in maternal blood. Annu. Rev. Genom. Hum. Genet. 13 (2012), 285–306.
11. [11] Crowley, E., Di Nicolantonio, F., Loupakis, F., Bardelli, A., Liquid biopsy: monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 10 (2013), 472–484.
12. [12] Diaz, L.A. Jr., Bardelli, A., Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32 (2014), 579–586.
13. [13] Diaz, L.A. Jr., Williams, R.T., Wu, J., Kinde, I., Hecht, J.R., Berlin, J., Allen, B., Bozic, I., Reiter, J.G., Nowak, M.A., Kinzler, K.W., Oliner, K.S., Vogelstein, B., The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486 (2012), 537–540.
14. [14] Murtaza, M., Dawson, S.J., Tsui, D.W., Gale, D., Forshew, T., Piskorz, A.M., Parkinson, C., Chin, S.F., Kingsbury, Z., Wong, A.S., Marass, F., Humphray, S., Hadfield, J., Bentley, D., Chin, T.M., Brenton, J.D., Caldas, C., Rosenfeld, N., Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497 (2013), 108–112.
15. [15] Murtaza, M., Dawson, S.J., Pogrebniak, K., Rueda, O.M., Provenzano, E., Grant, J., Chin, S.F., Tsui, D.W., Marass, F., Gale, D., Ali, H.R., Shah, P., Contente-Cuomo, T., Farahani, H., Shumansky, K., Kingsbury, Z., Humphray, S., Bentley, D., Shah, S.P., Wallis, M., Rosenfeld, N., Caldas, C., Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat. Commun., 6, 2015, 87.
16. [16] Oxnard, G.R., Paweletz, C.P., Kuang, Y., Mach, S.L., O'Connell, A., Messineo, M.M., Luke, J.J., Butaney, M., Kirschmeier, P., Jackman, D.M., Janne, P.A., Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 20 (2014), 1698–1705.
17. [17] Dawson, S.J., Tsui, D.W., Murtaza, M., Biggs, H., Rueda, O.M., Chin, S.F., Dunning, M.J., Gale, D., Forshew, T., Mahler-Araujo, B., Rajan, S., Humphray, S., Becq, J., Halsall, D., Wallis, M., Bentley, D., Caldas, C., Rosenfeld, N., Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368 (2013), 1199–1209.
18. [18] Bettegowda, C., Sausen, M., Leary, R.J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B.R., Wang, H., Luber, B., Alani, R.M., Antonarakis, E.S., Azad, N.S., Bardelli, A., Brem, H., Cameron, J.L., Lee, C.C., Fecher, L.A., Gallia, G.L., Gibbs, P., Le, D., Giuntoli, R.L., Goggins, M., Hogarty, M.D., Holdhoff, M., Hong, S.M., Jiao, Y., Juhl, H.H., Kim, J.J., Siravegna, G., Laheru, D.A., Lauricella, C., Lim, M., Lipson, E.J., Marie, S.K., Netto, G.J., Oliner, K.S., Olivi, A., Olsson, L., Riggins, G.J., Sartore-Bianchi, A., Schmidt, K., Shih l, M., Oba-Shinjo, S.M., Siena, S., Theodorescu, D., Tie, J., Harkins, T.T., Veronese, S., Wang, T.L., Weingart, J.D., Wolfgang, C.L., Wood, L.D., Xing, D., Hruban, R.H., Wu, J., Allen, P.J., Schmidt, C.M., Choti, M.A., Velculescu, V.E., Kinzler, K.W., Vogelstein, B., Papadopoulos, N., Diaz, L.A. Jr., Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med., 6, 2014, 224ra224.
19. [19] Marchetti, A., Palma, J.F., Felicioni, L., De Pas, T.M., Chiari, R., Del Grammastro, M., Filice, G., Ludovini, V., Brandes, A.A., Chella, A., Malorgio, F., Guglielmi, F., De Tursi, M., Santoro, A., Crino, L., Buttitta, F., Early prediction of response to tyrosine kinase inhibitors by quantification of egfr mutations in plasma of NSCLC patients. J. Thorac. Oncol. 10 (2015), 1437–1443.
20. [20] Kim, E.S., Hirsh, V., Mok, T., Socinski, M.A., Gervais, R., Wu, Y.L., Li, L.Y., Watkins, C.L., Sellers, M.V., Lowe, E.S., Sun, Y., Liao, M.L., Osterlind, K., Reck, M., Armour, A.A., Shepherd, F.A., Lippman, S.M., Douillard, J.Y., Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372 (2008), 1809–1818.
21. [21] Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.J., Chewaskulyong, B., Jiang, H., Duffield, E.L., Watkins, C.L., Armour, A.A., Fukuoka, M., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361 (2009), 947–957.
22. [22] Barra, G.B., Santa Rita, T.H., de Almeida Vasques, J., Chianca, C.F., Nery, L.F., Santana Soares Costa, S., EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples. Clin. Biochem. 48 (2015), 976–981.
23. [23] El Messaoudi, S., Rolet, F., Mouliere, F., Thierry, A.R., Circulating cell free DNA: preanalytical considerations. Clin. Chim. Acta 424 (2013), 222–230.
24. [24] Diehl, F., Schmidt, K., Choti, M.A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S.A., Kinzler, K.W., Vogelstein, B., Diaz, L.A. Jr., Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14 (2008), 985–990.
25. [25] Norton, S.E., Lechner, J.M., Williams, T., Fernando, M.R., A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin. Biochem. 46 (2013), 1561–1565.
26. [26] Toro, P.V., Erlanger, B., Beaver, J.A., Cochran, R.L., VanDenBerg, D.A., Yakim, E., Cravero, K., Chu, D., Zabransky, D.J., Wong, H.Y., Croessmann, S., Parsons, H., Hurley, P.J., Lauring, J., Park, B.H., Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clin. Biochem. 48 (2015), 993–998.
27. [27] Wong, D., Moturi, S., Angkachatchai, V., Mueller, R., DeSantis, G., van den Boom, D., Ehrich, M., Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing. Clin. Biochem. 46 (2013), 1099–1104.
28. [28] Diaz, L.A., The promise of liquid biopsy in colorectal cancer. Clin. Adv. Hematol. Oncol 12 (2014), 688–689.
29. [29] Yong, E., Cancer biomarkers: written in blood. Nature 511 (2014), 524–526.
30. [30] Giacona, M.B., Ruben, G.C., Iczkowski, K.A., Roos, T.B., Porter, D.M., Sorenson, G.D., Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 17 (1998), 89–97.
31. [31] Jiang, P., Chan, C.W., Chan, K.C., Cheng, S.H., Wong, J., Wong, V.W., Wong, G.L., Chan, S.L., Mok, T.S., Chan, H.L., Lai, P.B., Chiu, R.W., Lo, Y.M., Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 1317–1325.
32. [32] Devonshire, A.S., Whale, A.S., Gutteridge, A., Jones, G., Cowen, S., Foy, C.A., Huggett, J.F., Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal. Bioanal. Chem. 406 (2014), 6499–6512.
33. [33] Mauger, F., Dulary, C., Daviaud, C., Deleuze, J.F., Tost, J., Comprehensive evaluation of methods to isolate, quantify, and characterize circulating cell-free DNA from small volumes of plasma. Anal. Bioanal. Chem. 407 (2015), 6873–6878.
34. [34] Breitbach, S., Tug, S., Helmig, S., Zahn, D., Kubiak, T., Michal, M., Gori, T., Ehlert, T., Beiter, T., Simon, P., Direct quantification of cell-free, circulating DNA from unpurified plasma. PLoS One, 9, 2014, e87838.
35. [35] L.Z. Sorber, K. Deschoolmeester, V. Roeyen, G. Rolfo, C. Pauwels, P., A Comparison of CfDNA Isolation Kits: Isolation and Quantification of Cell-Free DNA in Plasma. Unpublished results.
36. [36] Kadam, S.K., Farmen, M., Brandt, J.T., Quantitative measurement of cell-free plasma DNA and applications for detecting tumor genetic variation and promoter methylation in a clinical setting. J. Mol. Diagn. 14 (2012), 346–356.
37. [37] Su, Y.H., Wang, M., Brenner, D.E., Norton, P.A., Block, T.M., Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann. N. Y. Acad. Sci. 1137 (2008), 197–206.
38. [38] Page, K., Powles, T., Slade, M.J., Bella, D.E., Walker, R.A., Coombes, R.C., Shaw, J.A., The importance of careful blood processing in isolation of cell-free DNA. Ann. N. Y. Acad. Sci. 1075 (2006), 313–317.
39. [39] Wilkening, S., Hemminki, K., Thirumaran, R.K., Bermejo, J.L., Bonn, S., Forsti, A., Kumar, R., Determination of allele frequency in pooled DNA: comparison of three PCR-based methods. Biotechniques 39 (2005), 853–858.
40. [40] Duan, H., Lu, J., Lu, T., Gao, J., Zhang, J., Xu, Y., Wang, M., Wu, H., Liang, Z., Liu, T., Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status. Int. J. Clin. Exp. Pathol. 8 (2015), 13136–13145.
41. [41] Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., McCormack, R., EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J. Clin. Pathol. 66 (2013), 79–89.
42. [42] Iwama, E., Takayama, K., Harada, T., Okamoto, I., Ookubo, F., Kishimoto, J., Baba, E., Oda, Y., Nakanishi, Y., Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR. Oncotarget 6 (2015), 20466–20473.
43. [43] Laurent-Puig, P., Pekin, D., Normand, C., Kotsopoulos, S.K., Nizard, P., Perez-Toralla, K., Rowell, R., Olson, J., Srinivasan, P., Le Corre, D., Hor, T., El Harrak, Z., Li, X., Link, D.R., Bouche, O., Emile, J.F., Landi, B., Boige, V., Hutchison, J.B., Taly, V., Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin. Cancer Res. 21 (2015), 1087–1097.
44. [44] Tabernero, J., Lenz, H.J., Siena, S., Sobrero, A., Falcone, A., Ychou, M., Humblet, Y., Bouche, O., Mineur, L., Barone, C., Adenis, A., Yoshino, T., Goldberg, R.M., Sargent, D.J., Wagner, A., Laurent, D., Teufel, M., Jeffers, M., Grothey, A., Van Cutsem, E., Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 16 (2015), 937–948.
45. [45] Taniguchi, K., Uchida, J., Nishino, K., Kumagai, T., Okuyama, T., Okami, J., Higashiyama, M., Kodama, K., Imamura, F., Kato, K., Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin. Cancer Res. 17 (2011), 7808–7815.
46. [46] Paweletz, C.P., Sacher, A.G., Raymond, C.K., Alden, R.S., O'Connell, A., Mach, S.L., Kuang, Y., Gandhi, L., Kirschmeier, P., English, J.M., Lim, L.P., Janne, P.A., Oxnard, G.R., Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin. Cancer Res. 22 (2016), 915–922.
47. [47] Newman, A.M., Bratman, S.V., To, J., Wynne, J.F., Eclov, N.C., Modlin, L.A., Liu, C.L., Neal, J.W., Wakelee, H.A., Merritt, R.E., Shrager, J.B., Loo, B.W. Jr., Alizadeh, A.A., Diehn, M., An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20 (2014), 548–554.
48. [48] Guo, K., Zhang, Z., Han, L., Han, J., Wang, J., Zhou, Y., Liu, H., Tong, L., Li, X., Yan, X., Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer. Onco. Targets Ther. 8 (2015), 3289–3296.
49. [49] Li, B.T., Drilon, A., Johnson, M.L., Hsu, M., Sima, C.S., McGinn, C., Sugita, H., Kris, M.G., Azzoli, C.G., A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers. Ann. Oncol. 27 (2016), 154–159.
50. [50] Dowler Nygaard, A., Spindler, K.L., Pallisgaard, N., Andersen, R.F., Jakobsen, A., Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC. Oncol. Rep. 31 (2014), 969–974.
51. [51] Szpechcinski, A., Dancewicz, M., Kopinski, P., Kowalewski, J., Chorostowska-Wynimko, J., Real-time PCR quantification of plasma DNA in non-small cell lung cancer patients and healthy controls. Eur. J. Med. Res. 14:Suppl 4 (2009), 237–240.
52. [52] S. Little, Amplification-refractory mutation system (ARMS) analysis of point mutations. Curr Protoc Hum Genet 2001;Chapter 9: Unit 9 8.
53. [53] Vallee, A., Marcq, M., Bizieux, A., Kouri, C.E., Lacroix, H., Bennouna, J., Douillard, J.Y., Denis, M.G., Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer 82 (2013), 373–374.
54. [54] Xu, Q., Zhu, Y., Bai, Y., Wei, X., Zheng, X., Mao, M., Zheng, G., Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction. Onco. Targets Ther. 8 (2015), 1533–1541.
55. [55] Dong, L., Meng, Y., Sui, Z., Wang, J., Wu, L., Fu, B., Comparison of four digital PCR platforms for accurate quantification of DNA copy number of a certified plasmid DNA reference material. Sci. Rep., 5, 2015, 13174.
56. [56] Morrison, T., Hurley, J., Garcia, J., Yoder, K., Katz, A., Roberts, D., Cho, J., Kanigan, T., Ilyin, S.E., Horowitz, D., Dixon, J.M., Brenan, C.J., Nanoliter high throughput quantitative PCR. Nucleic Acids Res., 34, 2006, e123.
57. [57] Huggett, J.F., Whale, A., Digital, P.C.R., as a novel technology and its potential implications for molecular diagnostics. Clin. Chem. 59 (2013), 1691–1693.
58. [58] Taly, V., Pekin, D., Benhaim, L., Kotsopoulos, S.K., Le Corre, D., Li, X., Atochin, I., Link, D.R., Griffiths, A.D., Pallier, K., Blons, H., Bouche, O., Landi, B., Hutchison, J.B., Laurent-Puig, P., Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin. Chem. 59 (2013), 1722–1731.
59. [59] Schiavon, G., Hrebien, S., Garcia-Murillas, I., Cutts, R.J., Pearson, A., Tarazona, N., Fenwick, K., Kozarewa, I., Lopez-Knowles, E., Ribas, R., Nerurkar, A., Osin, P., Chandarlapaty, S., Martin, L.A., Dowsett, M., Smith, I.E., Turner, N.C., Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci. Transl. Med., 7, 2015, 313ra182.
60. [60] Diehl, F., Li, M., He, Y., Kinzler, K.W., Vogelstein, B., Dressman, D., BEAMing single-molecule PCR on microparticles in water-in-oil emulsions. Nat. Methods 3 (2006), 551–559.
61. [61] Meldrum, C., Doyle, M.A., Tothill, R.W., Next-generation sequencing for cancer diagnostics: a practical perspective. Clin. Biochem. Rev. 32 (2011), 177–195.
62. [62] Forshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D.W., Kaper, F., Dawson, S.J., Piskorz, A.M., Jimenez-Linan, M., Bentley, D., Hadfield, J., May, A.P., Caldas, C., Brenton, J.D., Rosenfeld, N., Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med., 4, 2012, 136ra168.
63. [63] Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K.W., Vogelstein, B., Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 9530–9535.
64. [64] Turke, A.B., Zejnullahu, K., Wu, Y.L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., Lindeman, N.I., Murphy, C., Akhavanfard, S., Yeap, B.Y., Xiao, Y., Capelletti, M., Iafrate, A.J., Lee, C., Christensen, J.G., Engelman, J.A., Janne, P.A., Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17 (2010), 77–88.
65. [65] Paweletz, C.P., Sacher, A.G., Raymond, C.K., Alden, R.S., O'Connell, A., Mach, S.L., Kuang, Y., Gandhi, L., Kirschmeier, P., English, J.M., Lim, L.P., Janne, P.A., Oxnard, G.R., Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin. Cancer Res. 22 (2016), 915–922.
66. [66] Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., Apicella, M., Migliardi, G., Galimi, F., Lauricella, C., Zanon, C., Perera, T., Veronese, S., Corti, G., Amatu, A., Gambacorta, M., Diaz, L.A. Jr., Sausen, M., Velculescu, V.E., Comoglio, P., Trusolino, L., Di Nicolantonio, F., Giordano, S., Siena, S., Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3 (2013), 658–673.
67. [67] Jeffery M, Hickey BE, Hider PN., Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007: CD002200.
68. [68] Srikantharajah, D., Ghuman, A., Nagendran, M., Maruthappu, M., Is computed tomography follow-up of patients after lobectomy for non-small cell lung cancer of benefit in terms of survival. Interact. Cardiovasc. Thorac. Surg. 15 (2012), 893–898.
69. [69] Szpechcinski, A., Rudzinski, P., Kupis, W., Langfort, R., Orlowski, T., Chorostowska-Wynimko, J., Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules. Cancer Lett. 374 (2016), 202–207.
70. [70] Sozzi, G., Conte, D., Mariani, L., Lo Vullo, S., Roz, L., Lombardo, C., Pierotti, M.A., Tavecchio, L., Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61 (2001), 4675–4678.
71. [71] Rainer, T.H., Lam, N.Y., Circulating nucleic acids and critical illness. Ann. N. Y. Acad. Sci. 1075 (2006), 271–277.
72. [72] Casoni, G.L., Ulivi, P., Mercatali, L., Chilosi, M., Tomassetti, S., Romagnoli, M., Ravaglia, C., Gurioli, C., Gurioli, C., Zoli, W., Silvestrini, R., Poletti, V., Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. Int. J. Biol. Mark. 25 (2010), 229–235.
73. [73] Nygaard, A.D., Holdgaard, P.C., Spindler, K.L., Pallisgaard, N., Jakobsen, A., The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. Br. J. Cancer 110 (2014), 363–368.
74. [74] Sato, K.A., Hachiya, T., Iwaya, T., Kume, K., Matsuo, T., Kawasaki, K., Abiko, Y., Akasaka, R., Matsumoto, T., Otsuka, K., Nishizuka, S.S., Individualized mutation detection in circulating tumor DNA for monitoring colorectal tumor burden using a cancer-associated gene sequencing panel. PLoS One, 11, 2016, e0146275.
75. [75] Qin, Z., Ljubimov, V.A., Zhou, C., Tong, Y., Liang, J., Cell-free circulating tumor DNA in cancer. Chin. J. Cancer, 35, 2016, 36.
76. [76] Dacic, S., Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. J. Clin. Pathol. 66 (2013), 870–874.
77. [77] Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J.M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M.A., Terrasa, J., Munoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J.L., Sanchez, J.J., Molina, M.A., Taron, M., Paz-Ares, L., Spanish Lung Cancer Group in collaboration with Groupe Francais de P-C and Associazione Italiana Oncologia T, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13 (2012), 239–246.
78. [78] Wu, Y.L., Zhou, C., Hu, C.P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J.H., Lee, K.Y., Xu, C.R., Massey, D., Kim, M., Shi, Y., Geater, S.L., Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 15 (2014), 213–222.
79. [79] Arcila, M.E., Oxnard, G.R., Nafa, K., Riely, G.J., Solomon, S.B., Zakowski, M.F., Kris, M.G., Pao, W., Miller, V.A., Ladanyi, M., Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin. Cancer Res. 17 (2011), 1169–1180.
80. [80] Sequist, L.V., Waltman, B.A., Dias-Santagata, D., Digumarthy, S., Turke, A.B., Fidias, P., Bergethon, K., Shaw, A.T., Gettinger, S., Cosper, A.K., Akhavanfard, S., Heist, R.S., Temel, J., Christensen, J.G., Wain, J.C., Lynch, T.J., Vernovsky, K., Mark, E.J., Lanuti, M., Iafrate, A.J., Mino-Kenudson, M., Engelman, J.A., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med., 3, 2011, 75ra26.
81. [81] Wang, Z., Chen, R., Wang, S., Zhong, J., Wu, M., Zhao, J., Duan, J., Zhuo, M., An, T., Wang, Y., Bai, H., Wang, J., Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. PLoS One, 9, 2014, e110780.
82. [82] Sorensen, B.S., Wu, L., Wei, W., Tsai, J., Weber, B., Nexo, E., Meldgaard, P., Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 120 (2014), 3896–3901.
83. [83] Finlay, M.R., Anderton, M., Ashton, S., Ballard, P., Bethel, P.A., Box, M.R., Bradbury, R.H., Brown, S.J., Butterworth, S., Campbell, A., Chorley, C., Colclough, N., Cross, D.A., Currie, G.S., Grist, M., Hassall, L., Hill, G.B., James, D., James, M., Kemmitt, P., Klinowska, T., Lamont, G., Lamont, S.G., Martin, N., McFarland, H.L., Mellor, M.J., Orme, J.P., Perkins, D., Perkins, P., Richmond, G., Smith, P., Ward, R.A., Waring, M.J., Whittaker, D., Wells, S., Wrigley, G.L., Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem. 57 (2014), 8249–8267.
84. [84] Cross, D.A., Ashton, S.E., Ghiorghiu, S., Eberlein, C., Nebhan, C.A., Spitzler, P.J., Orme, J.P., Finlay, M.R., Ward, R.A., Mellor, M.J., Hughes, G., Rahi, A., Jacobs, V.N., Red Brewer, M., Ichihara, E., Sun, J., Jin, H., Ballard, P., Al-Kadhimi, K., Rowlinson, R., Klinowska, T., Richmond, G.H., Cantarini, M., Kim, D.W., Ranson, M.R., Pao, W., AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4 (2014), 1046–1061.
85. [85] Watanabe, M., Kawaguchi, T., Isa, S., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., Kakegawa, S., Yamashita, M., Kataoka, K., Ichinose, Y., Takeuchi, Y., Sakamoto, K., Matsumura, A., Koh, Y., Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR. Clin. Cancer Res. 21 (2015), 3552–3560.
86. [86] Thress, K.S., Paweletz, C.P., Felip, E., Cho, B.C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., Ercan, D., Matthews, S.E., Cantarini, M., Barrett, J.C., Janne, P.A., Oxnard, G.R., Acquired, E.G.F.R., C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21 (2015), 560–562.
87. [87] Watanabe, S., Tanaka, J., Ota, T., Kondo, R., Tanaka, H., Kagamu, H., Ichikawa, K., Koshio, J., Baba, J., Miyabayashi, T., Narita, I., Yoshizawa, H., Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer, 11, 2011, 1.
88. [88] Becker, A., Crombag, L., Heideman, D.A., Thunnissen, F.B., van Wijk, A.W., Postmus, P.E., Smit, E.F., Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur. J. Cancer 47 (2011), 2603–2606.
89. [89] Jiang, S.Y., Zhao, J., Wang, M.Z., Huo, Z., Zhang, J., Zhong, W., Xu, Y., Small-cell lung cancer transformation in patients with pulmonary adenocarcinoma: a case report and review of literature. Medicine (Baltimore), 95, 2016, e2752.
90. [90] Nygaard, A.D., Garm Spindler, K.L., Pallisgaard, N., Andersen, R.F., Jakobsen, A., The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer 79 (2013), 312–317.
91. [91] Camps, C., Jantus-Lewintre, E., Cabrera, A., Blasco, A., Sanmartin, E., Gallach, S., Caballero, C., del Pozo, N., Rosell, R., Guijarro, R., Sirera, R., The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer 72 (2011), 365–369.
92. [92] Mellema, W.W., Masen-Poos, L., Smit, E.F., Hendriks, L.E., Aerts, J.G., Termeer, A., Goosens, M.J., Smit, H.J., van den Heuvel, M.M., van der Wekken, A.J., Herder, G.J., Krouwels, F.H., Stigt, J.A., van den Borne, B.E., Haitjema, T.J., Staal-Van den Brekel, A.J., van Heemst, R.C., Pouw, E., Dingemans, A.M., Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer. Lung Cancer 90 (2015), 249–254.
93. [93] Pan, W., Yang, Y., Zhu, H., Zhang, Y., Zhou, R., Sun, X., KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies. Oncotarget 7 (2016), 8373–8388.
94. [94] Kitazono, S., Fujiwara, Y., Tsuta, K., Utsumi, H., Kanda, S., Horinouchi, H., Nokihara, H., Yamamoto, N., Sasada, S., Watanabe, S., Asamura, H., Tamura, T., Ohe, Y., Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non–small-cell lung cancer. Clin. Lung Cancer 16 (2015), 385–390.
95. [95] Lim, C., Sung, M., Shepherd, F.A., Nouriany, N., Sawczak, M., Paul, T., Perera-Low, N., Foster, A., Zawisza, D., Feld, R., Liu, G., Leighl, N.B., Patients with advanced non-small cell lung cancer: are research biopsies a barrier to participation in clinical trials. J. Thorac. Oncol. 11 (2016), 79–84.
96. [96] Thress, K.S., Brant, R., Carr, T.H., Dearden, S., Jenkins, S., Brown, H., Hammett, T., Cantarini, M., Barrett, J.C., EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90 (2015), 509–515.
97. [97] Solomon, B.J., Mok, T., Kim, D.W., Wu, Y.L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Iyer, S., Reisman, A., Wilner, K.D., Tursi, J., Blackhall, F., Investigators, P., First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371 (2014), 2167–2177.
98. [98] Nilsson, R.J., Balaj, L., Hulleman, E., van Rijn, S., Pegtel, D.M., Walraven, M., Widmark, A., Gerritsen, W.R., Verheul, H.M., Vandertop, W.P., Noske, D.P., Skog, J., Wurdinger, T., Blood platelets contain tumor-derived RNA biomarkers. Blood 118 (2011), 3680–3683.
99. [99] Best, M.G., Sol, N., Kooi, I., Tannous, J., Westerman, B.A., Rustenburg, F., Schellen, P., Verschueren, H., Post, E., Koster, J., Ylstra, B., Ameziane, N., Dorsman, J., Smit, E.F., Verheul, H.M., Noske, D.P., Reijneveld, J.C., Nilsson, R.J., Tannous, B.A., Wesseling, P., Wurdinger, T., RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 28 (2015), 666–676.
100. [100] Skog, J., Wurdinger, T., van Rijn, S., Meijer, D.H., Gainche, L., Sena-Esteves, M., Curry, W.T. Jr., Carter, B.S., Krichevsky, A.M., Breakefield, X.O., Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10 (2008), 1470–1476.
101. [101] Goubran, H.A., Stakiw, J., Radosevic, M., Burnouf, T., Platelets effects on tumor growth. Semin. Oncol. 41 (2014), 359–369.
102. [102] Nilsson, R.J., Karachaliou, N., Berenguer, J., Gimenez-Capitan, A., Schellen, P., Teixido, C., Tannous, J., Kuiper, J.L., Drees, E., Grabowska, M., van Keulen, M., Heideman, D.A., Thunnissen, E., Dingemans, A.M., Viteri, S., Tannous, B.A., Drozdowskyj, A., Rosell, R., Smit, E.F., Wurdinger, T., Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget 7 (2016), 1066–1075.
103. [103] Jamal-Hanjani, M., Wilson, G.A., Horswell, S., Mitter, R., Sakarya, O., Constantin, T., Salari, R., Kirkizlar, E., Sigurjonsson, S., Pelham, R., Kareht, S., Zimmermann, B., Swanton, C., Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann. Oncol. 27 (2016), 862–867.
104. [104] Fleischhacker, M., Dietrich, D., Liebenberg, V., Field, J.K., Schmidt, B., The role of DNA methylation as biomarkers in the clinical management of lung cancer. Expert Rev. Respir. Med. 7 (2013), 363–383.
105. [105] Diaz-Lagares, A., Mendez-Gonzalez, J., Hervas, D., Saigi, M., Pajares, M.J., Garcia, D., Crujerias, A.B., Pio, R., Montuenga, L.M., Zulueta, J., Nadal, E., Rosell, A., Esteller, M., Sandoval, J., A novel epigenetic signature for early diagnosis in lung cancer. Clin. Cancer Res., 2016 [epub ahead of print].